Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases1
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
VSL#3 (VSL#3) is a high-concentration probiotic preparation of eight live freeze-dried bacterial species that are normal components of the human gastrointestinal microflora, including four strains of lactobacilli (Lactobacillus casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), three strains of bifidobacteria (Bifidobacterium longum, B. breve, and B. infantis), and Streptococcus salivarius subsp. thermophilus. Data from noncomparative trials suggest that VSL#3 has clinical potential in the treatment of active mild to moderate ulcerative colitis and as maintenance therapy for patients with ulcerative colitis in remission. In addition, a randomized, open-label, multicenter trial showed that VSL#3 in combination with low-dose balsalazide (a prodrug of mesalazine [mesalamine; 5-aminosalicylic acid]) was more effective than standard doses of basalazide or mesalazine monotherapy in the treatment of acute mild to moderate ulcerative colitis. Randomized, double-blind, placebo-controlled studies have shown VSL#3 is effective in preventing the onset of acute pouchitis in patients with newly formed surgical pouches, and in maintaining remission following antibacterial treatment of acute pouchitis in patients with a history of refractory or recurrent pouchitis. Treatment guidelines from the US and the UK include VSL#3 as a therapeutic option for the prevention of pouchitis relapse in patients with chronic pouchitis. In general, VSL#3 was well tolerated in clinical trials. Large, well designed, controlled confirmatory clinical trials will further determine the place of VSL#3 in the treatment of ulcerative colitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This result is consistent with clinical studies suggesting that probiotics, including VSL#3, can significantly enhance intestinal barrier function in vivo (18).”
From Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip (2016) · cites this paper as [18]
Citations
Cites
Gionchetti, P., Rizzello, F., Venturi, A., Brigidi, P., Matteuzzi, D., Bazzocchi, G., Poggioli, G., Miglioli, M., & Campieri, M. (2000) · Gastroenterology · doi:10.1053/gast.2000.9370 · Cited by 1,486
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I. C., Nicholls, R. J., Gionchetti, P., Campieri, M., & Kamm, M. A. (2004) · Gut · doi:10.1136/gut.53.1.108 · Cited by 913
Rachmilewitz, D., Katakura, K., Karmeli, F., Hayashi, T., Reinus, C., Rudensky, B., Akira, S., Takeda, K., Lee, J., Takabayashi, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.019 · Cited by 859
VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis
Bibiloni, R., Fedorak, R. N., Tannock, G. W., Madsen, K. L., Gionchetti, P., Campieri, M., De Simone, C., & Sartor, R. B. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41794.x · Cited by 744
Venturi, Gionchetti, Rizzello, Johansson, Zucconi, Brigidi, Matteuzzi, & Campieri (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00560.x · Cited by 567
Modulation of human dendritic cell phenotype and function by probiotic bacteria
Hart, A. L., Lammers, K., Brigidi, P., Vitali, B., Rizzello, F., Gionchetti, P., Campieri, M., Kamm, M. A., Knight, S. C., & Stagg, A. J. (2004) · Gut · doi:10.1136/gut.2003.037325 · Cited by 555
DNA from probiotic bacteria modulates murine and human epithelial and immune function
Jijon, H., Backer, J., Diaz, H., Yeung, H., Thiel, D., McKaigney, C., De Simone, C., & Madsen, K. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.003 · Cited by 321
Lammers, K. M., Brigidi, P., Vitali, B., Gionchetti, P., Rizzello, F., Caramelli, E., Matteuzzi, D., & Campieri, M. (2003) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(03)00144-5 · Cited by 284
Tursi, A., Brandimarte, G., Giorgetti, G. M., Forti, G., Modeo, M. E., & Gigliobianco, A. (2004) · PubMed · Cited by 266
Cited by
Probiotics, Prebiotics, and Synbiotics
de Vrese, M., & Schrezenmeir, J. (2008) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2008_097 · Cited by 1,028
Kim, H. J., Li, H., Collins, J. J., & Ingber, D. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522193112 · Cited by 922
Probiotics and Prebiotics: Effects on Diarrhea1
de Vrese, M., & Marteau, P. R. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.3.803s · Cited by 312
Probiotics and prebiotics in inflammatory bowel disease: microflora ‘on the scope’
Damaskos, D., & Kolios, G. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03096.x · Cited by 151
Panwar, H., Calderwood, D., Grant, I. R., Grover, S., & Green, B. D. (2014) · European Journal of Nutrition · doi:10.1007/s00394-013-0649-9 · Cited by 126
“For example, VSL#3 is a probiotic bacterial preparation containing 450–900 billion live bacteria that has been classified by the FDA as a ‘medicinal food’ designated for the dietary management of three major gastrointestinal conditions: ulcerative colitis, ileal pouch and irritable bowel syndrome [22, 23].”
Background
Metadata
- Authors
- Chapman, T. M., Plosker, G. L., & Figgitt, D. P.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Plosker, Greg L
- ORCID
- Figgitt, David P
- Venue
- BioDrugs
- Published
- 2007
- Volume
- 21
- Issue
- 1
- Pages
- 61-63
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- OpenAlex
- W2000806325
- Cited by
- 48
- References
- 15
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 1 · 2020: 1 · 2018: 1 · 2017: 4 · 2015: 5 · 2014: 2 · 2013: 3 · 2012: 4
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- BioDrugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- VSL#3, probiotics, ulcerative colitis, Crohn's disease, inflammatory bowel disease, balsalazide, 5-aminosalicylic acid, pouchitis, Lactobacillus, Bifidobacterium, Streptococcus salivarius subsp. thermophilus, maintenance therapy, remission
- MeSH terms
- Humans, Inflammatory Bowel Diseases, Randomized Controlled Trials as Topic, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases1. https://app.cochat.ai/papers/10.2165/00063030-200721010-00007
- The paper
- Chapman, T. M., Plosker, G. L., & Figgitt, D. P. (2007). Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases1. BioDrugs. https://doi.org/10.2165/00063030-200721010-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.